BioprintingCellular Agriculture

Fluicell advancing Biopixlar platform for therapeutic bioprinting

BioRej Advance partnership program will bring together industry and academia

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Swedish bioprinting startup Fluicell made a big break into the bioprinting market in 2019 with the launch of its Biopixlar system, capable of 2D and 3D printing. Now, over a year since the initial launch, the company is still developing its technology to advance its viability for therapeutic applications. Specifically, Fluicell is focused on creating advanced therapy medicinal products (ATMP) to be used to treat various diseases and conditions. To support ongoing advancements, the company has launched a partnership program, BioRej Advance, which will bring together players from the pharmaceutical industry and academia.

The Biopixlar is a high-resolution, scalable platform based on Fluicell’s proprietary microfluidic bioprinting technology. The system also comprises a specialized software program and a gamepad interface. Fluicell believes its technology could help develop treatments for certain conditions which have been challenging to treat using more conventional methods. For instance, Biopixlar could be used to produce engineered tissue products for cardiac repair or to treat diabetes or macular degeneration.

Fluicell Biopixlar

To achieve the goal of developing bioprinted tissues and therapeutics, Fluicell has a three-phase plan, beginning with the expansion of its current activities developing human in vitro tissue models for research. The second phase will include in vivo preclinical studies, and the third phase will consist of testing the engineered tissue in clinical trials.

“This is a historical and very exciting moment for Fluicell,” said Victoire Viannay, CEO of Fluicell. “We now take the first step to fully realize the potential inherent in the Biopixlar platform. Our ongoing R&D activities have shown a clear path forward and we now accelerate our efforts to establish Fluicell as an innovation leader within regenerative medicine therapeutics.”

The BioRej Advance partnership program will further enable Fluicell to realize its ambitions by bringing together players from academia and the pharmaceutical industry. The work will draw on Fluicell’s existing R&D, which has focused on demonstrating Biopixlar’s ability to recreate biological tissues by printing them on transplantable membranes. These membranes can then be used for research purposes or for therapeutic applications, like as a tissue patch for restoring organ function.

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*